新股消息 | 英派药业拟港股上市 中国证监会要求补充说明历次增资及股权转让定价依据等事项

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for 10 companies, including Yingpai Pharmaceutical, which is required to clarify the pricing basis for past capital increases and share transfers, and whether there have been any instances of shareholding representation since its establishment [1] - Yingpai Pharmaceutical submitted its listing application to the Hong Kong Stock Exchange on September 26, with Goldman Sachs and CICC as joint sponsors [1] - The CSRC has requested legal opinions on the compliance of the company's past equity changes, including whether there are any unfulfilled capital contributions or irregularities in the contribution methods [1][2] Group 2 - Yingpai Pharmaceutical, established in 2009, is a biotechnology company focused on the global development of precision cancer therapies based on synthetic lethality mechanisms [2] - The company has developed a comprehensive and advanced synthetic lethality product portfolio and is one of only three companies globally with both commercial-stage PARP1/2 inhibitors and clinical-stage next-generation PARP1 selective inhibitors [2] - The core product, Senaparib, is a PARP1/2 inhibitor approved in China for first-line maintenance treatment of ovarian cancer in January 2025, showing the greatest progression-free survival benefit among approved PARP inhibitors for this indication [2]